We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
AMVUTTRA Medison Pharma Australia Pty Ltd
Product name
AMVUTTRA
Sponsor
Accepted date
Sep-2025
Active ingredients
vutrisiran sodium
Proposed indication
Amvuttra (vutrisiran sodium) is proposed for the treatment of hereditary transthyretin amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy (hATTR-PN).
Amvuttra (vutrisiran sodium) is indicated for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).
Amvuttra (vutrisiran sodium) is indicated for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).
Application type
C (new indication)
Publication date
Sep-2025
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.